Views: 0 Author: Site Editor Publish Time: 2025-07-08 Origin: Site
Diosmin, a citrus-derived flavonoid, has long been used in the treatment of chronic venous insufficiency (CVI) and hemorrhoidal disease. However, latest clinical research on diosmin 2025 reveals that this compound may offer far more — with promising roles in postoperative recovery, anti-inflammatory therapy, and even antiviral defense.
The use of diosmin for chronic venous insufficiency is well-established. It improves venous tone, lymphatic drainage, and microcirculation. When combined with hesperidin, the duo delivers greater symptom relief — including reduced leg swelling, pain, and cramps — than either alone.
Clinical studies consistently support the diosmin and hesperidin combination benefits, making it a standard treatment in vascular health.
Recent research highlights the diosmin antioxidant and anti-inflammatory effects:
Diosmin inhibits inflammatory mediators like COX‑2, iNOS, and NF‑κB.
In vitro, it induces G2/M cell cycle arrest and apoptosis in liver, colon, and breast cancer cells via p53, p21, p27 pathways.
In animal models, it reduces TNF‑α, LTB4, and MDA levels, easing tissue inflammation and oxidative stress.
These properties support diosmin’s broader application in diseases involving chronic inflammation and oxidative damage.
A 2024 multicenter RCT revealed a novel application: diosmin significantly reduced lower limb swelling and pain after total knee arthroplasty (TKA) — without increasing adverse events.
This positions diosmin as a safe, non-opioid adjunct for surgical recovery, especially in orthopedics.
Among the most exciting discoveries is the diosmin antiviral activity against influenza. A 2025 Nature partner journal study demonstrated that diosmin:
Binds to viral NS1, HA, and NA proteins, blocking entry
Inhibits viral RNA replication (IC₅₀ ≈ 2.9 µM)
Activates interferon-stimulated genes (ISGs)
This finding marks diosmin as a promising natural antiviral candidate for respiratory infections like H1N1.
Diosmin is currently being studied in a variety of clinical trials:
Ulcerative Colitis: Phase I/II trial with mesalamine (NCT05626166)
Rheumatoid Arthritis: Phase III study on inflammation control and MTX liver toxicity
NAFLD: Investigating metabolic and liver health benefits
DOMS: Evaluating muscle soreness relief after exercise
These studies underscore diosmin’s expanding role in gastrointestinal, autoimmune, metabolic, and recovery medicine.
From vascular health to inflammation, viral infections, and surgical recovery, diosmin is transforming from a traditional vein remedy into a multi-functional pharmaceutical ingredient. Supported by the latest clinical research on diosmin 2025, its future in modern therapeutics looks increasingly promising.
